Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.